Eligo Bioscience Secures €27.7 Million to Advance Microbiome Gene-Editing Platform Follow Dec 05, 2023 · 1 min read
Eligo Bioscience Secures €27.7 Million to Advance Microbiome Gene-Editing Platform
Share this

Eligo Bioscience, a pioneer in gene-editing therapies targeting the human microbiome, has raised €27.7 million in a Series B funding round. The financing was led by Sanofi Ventures, with additional support from new investor Bpifrance and existing backers Khosla Ventures and Seventure Partners. The capital will drive Eligo’s lead program for acne vulgaris into clinical trials and expand its pipeline across other inflammatory conditions.

Eligo is developing a groundbreaking approach that edits bacterial genes within the microbiome to treat a variety of chronic diseases. The company’s platform offers unique delivery and precision editing capabilities that promise to unlock new therapeutic possibilities beyond traditional gene therapy. Eligo’s flagship product candidate EB005 applies this technology to moderate-severe acne through genetic modifications that reduce skin inflammation.

The Series B proceeds will enable critical preclinical and IND-enabling activities to progress EB005 into first-in-human trials. The funds will also facilitate the advancement of additional programs focused on other high-impact indications across dermatology and immuno-oncology.

Bpifrance and Sanofi Ventures join Eligo’s board as observers, alongside existing directors from Khosla Ventures and Seventure Partners. This experienced life science leadership will provide key guidance as Eligo enters a rapid growth phase advancing its robust pipeline of microbiome gene editing therapies.

You may be interestd in this brief interview of Xavier Duportet, CEO & Co-founder of Eligo Bioscience:

Written by Follow